CASI 制药公司将CID-103推进到下一剂量阶段,用于治疗免疫性血栓囊肿。 CASI Pharmaceuticals advances CID-103 to next dose phase for treating immune thrombocytopenia.

CASI制药公司已经得到其安全监测委员会的批准,将CID-103(一种潜在的抗CD38药物)的剂量提高到其免疫性血栓细胞激素(ITP)第一阶段研究的下一个阶段。 CASI Pharmaceuticals has received approval from its Safety Monitoring Committee to escalate the dose of CID-103, a potential anti-CD38 drug, to the next phase of its Phase 1 study for immune thrombocytopenia (ITP). 该药物在最初四个组群中表现出积极的安全性,没有出现严重不良事件。 The drug showed a positive safety profile in the initial four cohorts without serious adverse events. 该公司目前正在招募病人进行进一步测试,并计划在2026年初开始对肾上腺脱硫进行第一阶段研究。 The company is currently recruiting patients for further testing and plans to start a Phase 1 study for renal allograft rejection in early 2026.